Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Baclofen,Naloxone Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Pharnext
Deal Size : Undisclosed
Deal Type : Collaboration
CMTA and Pharnext Enter Biomarker Research Collaboration
Details : The primary objective of this collaboration is to identify and validate potential treatment responsive CMT1A biomarkers that could be further explored in future clinical studies, in particular the upcoming Phase III study of PXT3003, Pharnext’s lead dr...
Product Name : PXT3003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 09, 2020
Lead Product(s) : Baclofen,Naloxone Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Pharnext
Deal Size : Undisclosed
Deal Type : Collaboration